财中社11月13日电四环医药(00460)发布公告,建议分拆其附属公司轩竹生物并在联交所主板上市,同时进一步收购轩竹生物约3.6177%股权。根据公告,海南四环已与阳光人寿签订股权转让协议,决定以约3.08亿元收购该部分股权。此外,海南四环于2024年10月21日至11月8日间已完成对轩竹生物约3.3717%股权的收购,总代价约为2.88亿元。此次收购事项与前次收购事项合并计算,总代价约为5.96...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.